Stephen R. Bloom

Education Bloom was educated at Queens' College, Cambridge, where he was awarded a Master of Arts degree in 1968 and a Doctor of Medicine degree in 1979. He was elected a Fellow of the Royal Society (FRS) in 2013. His nomination reads: centred Bloom played a seminal role in establishing the biology and pathophysiology of the intrinsic endocrine system of the gastrointestinal tract, an area which he pioneered and which is now a major focus of basic and applied laboratories worldwide. Through the identification of clinical syndromes associated with overproduction of these hormones and experimental physiological studies in man, Bloom established the physiological effects of these hormones. Importantly, he recognised that several gut derived peptides powerfully influenced glucose homeostasis and/or appetite, insights which have led to major developments in the treatment of Type 2 diabetes and obesity. and the National Institute for Health Research (NIHR).

Bloom was also knighted in the Queen's 2012 New Year Honours, and awarded Fellowships of the Royal College of Physicians (FRCP), Royal College of Pathologists (FRCPath), the Academy of Medical Sciences (FMedSci) and the Royal Society of Biology (FRSB). Bloom is Chairman of a Biotechnology Company, Zihipp, which completed round A funding in January 2020. It specialises in peptide hormone analogues to treat obesity and diabetes.